Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …

Cardiac allograft vasculopathy (CAV) is a pathologic immune-mediated remodelling of the
vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

Prezados colegas, Grandes avanços no diagnóstico, monitorização e tratamento da
Insuficiência Cardíaca (IC) foram observados nos últimos anos, com impactos reais na …

Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac
transplantation. Recent insights have underscored the fact that innate and adaptive immune …

O transplante cardíaco persiste sendo o tratamento de escolha para a insuficiência cardíaca
refratária, apesar da grande melhora na expectativa de vida com o tratamento clínico …

Colvin‐Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future
direction. Clin Transplant 2011: 25: 175–184.© 2011 John Wiley & Sons A/S. Abstract …

Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the
heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as …

Cardiac allograft vasculopathy (CAV) is a unique accelerated form of coronary vascular
disease affecting heart transplant recipients. This complication is a significant contributor to …

Background: Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality after
heart transplantation (HT). Angiotensin-converting enzyme inhibitors (ACEIs) may retard the …